Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivabradine for POTS in Long-Haul COVID
NCT05481177Phase 4Unknown
- Sponsor
- Uniformed Services University of the Health Sciences
- Start
- Jun 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ivabradine in postural orthostatic tachycardia syndrome (POTS) and inappropriate sinus tachycardia (IST) (4 arms), sponsored by Uniformed Services University of the Health Sciences. Primary endpoint: Change in standing heart rate following 3 months treatment. Status: unknown.
02
Drugs
ivabradine
03
Conditions
postural orthostatic tachycardia syndrome (POTS)inappropriate sinus tachycardia (IST)
Beyond the preview
Go deeper on NCT05481177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05481177.